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Abstract
Neonatal foals respond poorly to conventional vaccines. These vaccines typically target T-
helper (Th) cell dependent B-cell activation. However, Th2-cell immunity is impaired in foals
during the first three months of life. In contrast, neonatal basophils are potent interleukin-4
(IL-4) producers. The purpose of this study was to develop a novel vaccine triggering the
natural capacity of neonatal basophils to secrete IL-4 and to evaluate if vaccination resulted
in B-cell activation and antibody production against EHV-1 glycoprotein C (gC). Neonatal
vaccination was performed by oral biotinylated IgE (IgE-bio) treatment at birth followed by
intramuscular injection of a single dose of streptavidin-conjugated gC/IL-4 fusion protein
(Sav-gC/IL-4) for crosslinking of receptor-bound IgE-bio (group 1). Neonates in group 2
received the intramuscular Sav-gC/IL-4 vaccine only. Group 3 remained non-vaccinated at
birth. After vaccination, gC antibody production was not detectable. The ability of the vac-
cine to induce protection was evaluated by an EHV-1 challenge infection after weaning at 7
months of age. Groups 1 and 2 responded to EHV-1 infection with an earlier onset and over-
all significantly increased anti-gC serum antibody responses compared to control group 3.
In addition, group 1 weanlings had a decreased initial fever peak after infection indicating
partial protection from EHV-1 infection. This suggested that the neonatal vaccination
induced a memory B-cell response at birth that was recalled at weanling age after EHV-1
challenge. In conclusion, early stimulation of neonatal immunity via the innate arm of the
immune system can induce partial protection and increased antibody responses against
EHV-1.







Citation: Wagner B, Perkins G, Babasyan S, Freer
H, Keggan A, Goodman LB, et al. (2017) Neonatal
Immunization with a Single IL-4/Antigen Dose
Induces Increased Antibody Responses after
Challenge Infection with Equine Herpesvirus Type 1
(EHV-1) at Weanling Age. PLoS ONE 12(1):
e0169072. doi:10.1371/journal.pone.0169072
Editor: Ashlesh K Murthy, Midwestern University,
UNITED STATES
Received: October 5, 2016
Accepted: December 12, 2016
Published: January 3, 2017
Copyright: © 2017 Wagner et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All data are provided
in the manuscript and the supporting information.
Funding: Funding for this project was provided by
the Harry M. Zweig Memorial Fund for Equine
Research at Cornell University ‘A Novel Strategy to
Boost Antibody Production to EHV-1 in Neonates’
(http://vet.cornell.edu/research/Zweig/).
Monoclonal antibody development for horse cell
surface markers and cytokines was supported by
USDA grant #2005-01812 ‘The US Veterinary
Introduction
Equine herpesvirus type-1 (EHV-1) is member of the Varicellovirus genus in the Alphaherpes-
virinae subfamily that is highly prevalent in most equine populations [1–3]. EHV-1 has a sub-
stantial impact on equine health and equine industries worldwide through respiratory disease,
abortion, and encephalomyelopathy [3,4]. Most horses are first infected early in life and are
believed to remain latently infected for life. Latently infected, lactating mares act as source of
infection for their foals after birth, which in turn infect other foals and weanlings [1,2,5]. The
virus is spread with respiratory secretions via direct nose-to-nose contact or contact with
fomites. EHV-1 first infects the respiratory epithelium and quickly enters the retropharyngeal
lymphoid tissues. From here the virus spreads systemically via a cell-associated viremia, and
latency is established in the trigeminal ganglion and possibly some long-lived immune cells
[6,7]. EHV-1 is reactivated from the latent state and is shed again during times of stress, and
all clinical manifestations may be seen during recrudescence [3].
Currently, a number of vaccines against EHV-1, including inactivated and modified-live
virus vaccines, are available in the US and Europe. Through the use of these vaccines the
occurrence of abortion storms has generally decreased. However, EHV-1 outbreaks continue
to occur despite widespread vaccination [3,6,8]. Because very young foals react weakly to avail-
able vaccines, first vaccination is generally recommended between 4–6 months of age [9]. For
pathogens that are frequently transmitted early in life such as EHV-1, this vaccination regime
does not appear to be effective in preventing the initial EHV-1 infection of foals and conse-
quently the establishment of latent infection early in life.
All currently available EHV-1 vaccines are optimized to induce immunity in adult horses.
This is achieved by stimulating B-cells and antibody responses via Th-cell mediated pathways.
During their interaction with B-cells antigen-specific Th2-cells produce the cytokine interleu-
kin-4 (IL-4), formerly called B-cell stimulatory factor 1 [10]. IL-4 then initiates B-cell differen-
tiation and immunoglobulin class switching which results in formation of antigen-specific
memory B-cells and IgG secreting plasma cells.
Different research groups, including ours, have shown that T-cell responses and cytokine
production from T-cells are reduced and delayed in foals for at least three months after birth
[11–13]. We have previously shown that Th2-responses are almost undetectable in neonates.
IL-4 production by Th2-cells increased slowly with age and did not reach adult levels by three
months of age [13]. The findings offered an explanation for the weak immune response of
foals to currently available vaccines because induction of a classical Th2-response is a key
mechanism of most vaccines for initiating robust antibody titers.
Nevertheless, IgG antibody production occurs in foals before or shortly after birth for most
IgG isotypes [14]. Foal IgG1 is first produced in utero, can be detected after birth before colos-
trum uptake, exceeds maternal IgG1 by 5 weeks of age, and is up to 3-fold higher in serum of
2–3 months old foals compared to adult horse serum [15,16]. While maternal antibodies decline,
endogenous IgG3/5, and IgA synthesis were detectable within the first five to eight weeks of life
and reached adult serum levels by 3 months of age [15,16]. This suggests that IgG3/5 and IgA
production started within the first 2–3 weeks of life [14]. Only IgG4 antibodies showed a delay of
endogenous production in foals [16], and this may functionally be compensated by the increased
IgG1 concentrations in young foals. This suggests that IgG1 and IgG3/5 production start in foals
before Th2-immunity matures. The disconnection of IgG production and Th2-immunity early
in life suggests that neonatal B-cell stimulation and antibody production are initiated by Th2-in-
dependent, alternative pathways.
We have previously shown that IL-4 is produced in neonatal foals by basophils [17]. Neona-
tal foal basophils become equipped with Fc-receptor bound IgE within the first few hours after
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birth. These IgE antibodies originate from the dam, are transferred to the neonate in the colos-
trum, and can be found on basophils in the neonatal circulation for the first 2–3 months of life
[18]. Crosslinking of receptor-bound IgE leads to profound IL-4 production in, and secretion
from, the neonatal basophils. IL-4 production by neonatal basophils peaked at day 5 of age
[16] and can be induced during the first three months of life by IgE receptor crosslinking or
non-specific stimulation of basophils, while IL-4 production by Th2-cells is lacking [13]. In
adult people, basophils are potent IL-4 producers [19]. Various groups have shown in adult
humans or rodent models that basophils have important immune regulatory functions for the
induction of innate and adaptive immunity including the development of Th2-cells and the
regulation of antibody production [20–23].
Based on these findings, we hypothesized that neonatal basophil-derived IL-4 can directly
activate B-cell differentiation and provide a Th2-independent stimulation pathway for IgG
production in neonatal and young foals. Here, we evaluated a novel neonatal vaccine for
immunity and protection against EHV-1 infection by targeting IL-4 production in basophils
to induce B-cell activation after birth. The neonatal EHV-1 vaccine was composed of EHV-1
glycoprotein C (gC) antigen. EHV-1 gC is highly immunogenic in mouse models and the nat-
ural hosts [24–26], is involved in cell entry [27,28], was targeted for vaccine development in
rodents [29], and is able to interfere with the activation of the complement cascade by binding
to the complement component C3 [30]. EHV-1 gC-specific basophils and B-cell activation was
accomplished by oral treatment with biotinylated IgE (IgE-bio), which was then cross-linked
on the basophil surface with EHV-1 gC antigen by using a streptavidin-conjugated gC/IL-4
fusion protein (Sav-gC/IL-4). Neonatal foals received this vaccination at birth. An experimen-
tal EHV-1 challenge was performed at weanling age, a time of stress and thus increased risk
for EHV-1 transmission and disease, to test if the neonatal vaccination provided enhanced
immunity and thus protection against EHV-1 infection.
Materials and Methods
EHV-1 naïve foals
Fifteen neonatal foals from an EHV-1-free herd of Icelandic horses at Cornell University were
enrolled in this study. EHV-1 has not been reported in Iceland [31]. General and targeted sur-
veillance by PCR testing from abortions, respiratory or neurological cases in Iceland have been
negative for EHV-1 since monitoring began in 1990 (personal communication Dr. Vilhja´lmur
Svansson, University of Iceland, Keldur, Reykjavı´k). In contrast, EHV-4 occurs in Iceland. The
neonatal foals were offspring of 15 pregnant mares that were purchased from private owners,
bred in Iceland, and imported from Iceland to the US while 6–7 months pregnant in February
2012. Import quarantine for the mares was performed at an isolated facility at Cornell Univer-
sity under USDA/APHIS supervision. All horses were kept at this facility and had no contact
to other horses in the US prior to and for the duration of this study. The facility had restricted
access for people to avoid infection with common US pathogens and to maintain the EHV-
1-free status of the Icelandic herd. The mares were vaccinated against rabies and tetanus after
the import quarantine and then annually. They were and dewormed on a regular basis. The
mares were not vaccinated against EHV-1 or EHV-4 before foaling. The 15 foals were born at
the isolated facility within 3 weeks in June 2012 without complications. All foals suckled colos-
trum ad libatum. Due to the specific EHV-1-free status of the mares, the colostrum did not con-
tain EHV-1-specific maternal antibodies at birth. At birth, foals were randomly assigned to
three groups. All foals were experimentally challenged with EHV-1 at weanling age as outlined
below. After birth and before experimental EHV-1 infection, all foals were kept on pasture with
their mares. Grass hay was fed to all horses ad libatum. All foals were clinically healthy from
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birth to weanling age. They were first vaccinated against tetanus and rabies and dewormed with
ivermectin at 6 months of age but were not vaccinated or treated otherwise. The neonatal vacci-
nation, the experimental EHV-1 challenge and all sample collections for this study were carried
out in accordance with the recommendation in the Guide for the Care and Use of Laboratory
Animals of the National Institute of Health. The protocol was approved by the Institutional Ani-
mal Care and Use Committee at Cornell University (protocol #2011–0011). Since the study was
performed in horses the work also followed the Guide for Care and Use of Animals in Agricul-
tural Research and Teaching. All efforts were made to minimize suffering of the animals for
example by administering tranquilizers for nervous or excited horses before sampling. After the
end of this experimental study, all horses were kept at the facility at Cornell University as
research horses.
Neonatal EHV-1 vaccination
Fifteen neonatal foals were divided into three groups of five foals each. Group 1 (3 fillies, 2
colts) received IgE-bio at birth and before colostrum intake. The purification and biotinylation
of equine IgE [32,33] was performed as described in S1 File. A total of 1 mg IgE-bio was given
via nasogastric intubation in a total of 20–30 ml 0.9% saline solution. Group 2 (2 fillies, 3 colts)
did not receive IgE-bio at birth. On day 2 of life, group 1 and group 2 foals received an intra-
muscular (IM) injection of 0.5 mg Sav-gC/IL-4 into the left semitendonosus muscle. The
expression and purification of gC/IL-4 was performed as previously described [26,34]. Sav
coupling was described in detail in S1 File. Group 3 foals (1 filly, 4 colts) received neither IgE-
bio nor Sav-gC/IL-4 antigen.
Blood sample collection after neonatal vaccination
Blood samples were collected by jugular venipuncture with a vacutainer collection system and
a 20-gauge needle. Blood tubes without coagulant or with heparin were used for serum collec-
tion or peripheral blood mononuclear cell (PBMC) isolation, respectively. Serum samples for
antibody measurements were collected from all foals immediately after birth before IgE was
administrated (group 1) and before colostrum intake (all groups), on days 2 (before EHV-1
gC/IL-4 was given), 5, 12, 25 and 60 and 90 of age. Blood in tubes without coagulant was
allowed to clot and after centrifugation (3,000xg, RT, 15 min). Serum was collected and frozen
at –20˚C for later measurements of EHV-1-specific antibodies in serum. Heparinized blood
samples were obtained from neonatal foals on days 2 and 5 after birth for PBMC isolation and
basophil stimulation (S1 File).
EHV-1 Multiplex assay for EHV-1-specific total antibody and isotype
detection
An EHV-1 Multiplex assay was used for measuring total EHV-1 gC and gD-specific antibodies
in serum samples after neonatal vaccination. The EHV-1 Multiplex assay was also used to mea-
sure EHV-1 specific isotype responses in serum samples after experimental EHV-1 infection at
weanling age. The EHV-1 Multiplex assay for gC and gD antigens was described previously in
detail [26]. The assay correlates highly to EHV-1 SN-testing but has a much wider linear quan-
tification range and allows for Ig isotype analysis.
Experimental EHV-1 challenge infection at weanling age
At 7 months of age, the foals were weaned and moved to a separate pasture. Two days later (d-2),
foals were moved into the isolation barn with individual box stalls and allowed to acclimate for
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two days. The stalls did not allow the horses to have direct nose-to-nose contact. However, the
barn had a center hallway with the same airspace and horses were handled in the facility as one
group. Biosecurity precautions were taken by people upon entering and exiting the facility. No
other specific care was taken to prevent spread of virus from horse-to-horse by animal handlers.
Baseline serum and nasal secretion samples were taken the day before EHV-1 infection (d-1).
Baseline physical examination measurements were taken a day prior to and immediately before
EHV-1 infection on d0. Then, all horses were infected intranasally with 1 x 107 plaque-forming
units (PFU) of EHV-1 strain NY03 in 7 ml of saline with a mucosal atomizer device (Wolfe Tory
Medical, Salt Lake City, UT). The EHV-1 strain NY03 does not possess the D752-encoding single
nucleotide polymorphism and is typed as a “non-neurogenic” strain [35].
Clinical evaluation
Temperatures were taken in the morning and evening until day 7 post infection (pi) and then
once a day before samples were obtained in the morning. A fever was defined as a rectal tem-
perature of>101.5˚F (> 38.6˚C). Clinical scoring was performed daily until day 17 pi by an
equine clinician who was unaware of the treatment at birth or the group assignments. Scoring
was performed according to a clinical scoring system described by Furr and coworkers [36]
and included individual scores for nasal discharge, eye discharge, mandibular lymph nodes
and a neurologic score resulting in a daily total clinical score for each horse. Neurologic scor-
ing was performed by walking the horses in the aisle way of the isolation barn to assess for
ataxia.
Blood and nasal secretion samples after experimental EHV-1 infection
Blood samples were collected on days -1, 1 to 10, 12, 14, 19, 26, 40, 61, 122, 150, 172 and 220
pi. Serum samples were used for EHV-1 specific antibody multiplex analysis (until day 220 pi)
and for cytokine detection (until day 19 pi). PBMC were isolated from heparinized blood.
PBMC aliquots were used immediately for cellular stimulation assays to detect cytokines in
supernatants (until day 150 pi) and EHV-1-specific T-cells (until day 220 pi), as described
below. Snap frozen aliquots of 5 x 106 PBMC obtained from day -1 until day 14 pi were used
for EHV-1 PCR to determine viremia.
Nasal swabs were obtained on days -1, 1 to 10, 12, and 14 pi using two sterile, polyester
tipped swabs (Puritan Medical Products Company, LLC, Guilford, ME) placed in the nostril
contacting the nasal mucosa for up to 2–3 seconds. The swabs were placed directly into poly-
styrene tubes containing 1 ml of PBS. Samples were subsequently transported to the laboratory
where they were centrifuged at 200xg for 10 min at 4˚C and stored in two aliquots immediately
afterwards at -80˚C. One aliquot containing the pellet plus 200 μl of the solution above the pel-
let was used for EHV-1 PCR.
EHV-1 PCR
DNA was isolated from nasal swab samples to determine viral genome copy numbers in nasal
secretions by quantitative PCR targeting the gB gene [37] using purified amplicon standards
and 4 μl of template (from a 90 μl elution). Aliquots of 5 x 106 snap frozen PBMC pellets were
extracted and tested using the same assay with a positive cutoff imposed at the analytic limit of
100% detection. Cycle threshold (Ct) values were calculated based on the automated algorithm
on the Applied Biosystems 7500 platform. The quantitative PCR was performed at the Animal
Health Diagnostic Center at Cornell University.
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Cytokine and interferon detection by multiplex analysis
Cytokines and interferons (all called cytokines from here on) were determined in cell culture
supernatants from equine peripheral blood mononuclear cells (PBMC) using an fluorescent
beads-based equine cytokine multiplex assays for IFN-α, IL-4, IL-10, IL-17 and IFN-γ as previ-
ously described [38]. The Equine Cytokine Multiplex assay is available through the Animal
Health Diagnostic Center at Cornell University. IL-4, IL-10 and IFN-α were expressed in pg/ml
and IL-17 and IFN-γ were reported as U/ml.
In vitro re-stimulation of PBMC with EHV-1
EHV-1 re-stimulation of PBMC was performed using the EHV-1 strain RacL11 at a MOI of 1
as previously described [39,40]. The PMA/ionomycin stimulation [39,40] was used as a posi-
tive and viability control of the PBMC, and high cytokine values were measured after PMA/
ionomycin stimulation for all samples and cytokines described here.
Flow cytometric analysis of cytokine producing EHV-1 re-stimulated
T-cells
For flow cytometric analysis, cells were harvested after 48 hours of stimulation, fixed, permea-
bilized, and aliquots were triple-stained for (1) cell surface CD4 and CD8, and intracellular
IFN-γ expression, or (2) intracellular IL-4, IL-10 and IL-17A expression using directly labeled
antibodies and isotype-matched staining controls as previously described [13,40,41]. The cells
were analyzed in a FACS Canto II flow cytometer (BD Biosciences, San Diego, CA).
Statistical analysis
D’Agostino & Pearson normality tests indicated that values on most days were not normally dis-
tributed. All post EHV-1 challenge parameters were compared by repeated-measures ANOVAs
with Bonferroni post tests between all three neonatal vaccination groups. The intracellular cyto-
kines production by T-cells did not show any significant differences between the three groups
and changes were thus considered as not influenced by the neonatal vaccination. Intracellular
cytokines production by T-cells was analyzed for all 15 weanlings to describe the changes in
their cellular immunity to EHV-1 infection over time by nonparametric Friedman tests for
repeated measurements followed by Dunn’s tests. Each of the post infection time points was
compared to the pre-infection value. P-values of<0.05 were considered significant. The statisti-
cal analysis was performed and the graphs were created using GraphPad Prism 6 for Mac OS X,
version 6f.
Results
Immune response after neonatal EHV-1 vaccination
The binding of IgE-bio to equine cells, the IL-4 induction after IgE-bio crosslinking, and the
Sav-gC/IL-4 conjugation and were first evaluated in vitro (S2 File). IgE-bio bound to high-
affinity IgE receptors on equine basophils and crosslinking induced IL-4 secretion in vitro (S1
Fig). After neonatal vaccination, EHV-1 gC and gD-specific antibody values were measured in
sera of all foals immediately after birth, before and after neonatal EHV-1 vaccination until
foals were 3 months of age. Differences in gC or gD-specific antibodies were not observed
between the three groups (S2 File). In addition, IgE+ cells were stimulated ex vivo to test if the
vaccination resulted in detectable amounts of IL-4 secreting basophils in the circulation of the
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neonates. While anti-IgE stimulated IL-4 production by basophils, as expected, Sav-gC/IL-4
stimulation did not result in detectable percentages of IgE+/IL-4+ cells (S2 Fig).
Clinical signs, nasal EHV-1 shedding and viremia after EHV-1 infection
at weanling age
Experimental infection with EHV-1 strain NY03 at weanling age resulted in a short bi-phasic
fever in all weanlings. Body temperatures were lower in weanling group 1 (IgE-bio and Sav-gC/
IL-4 at birth) compared to the non-vaccinated control group 3 at 24 hours and 36 hours pi
(both p<0.05). At the latter time point, the body temperature of group 1 weanlings was also
lower than in group 2 (Sav-gC/IL-4 at birth) (p<0.01). This resulted in a lower initial fever peak
in group 1 weanlings compared to the other two groups in response to EHV-1 infection (Fig
1A). All foals showed serous to mildly discolored nasal secretions, and slightly to moderately
Fig 1. Body temperatures, clinical signs, nasal shedding and viremia after experimental infection of weanlings with the EHV-
1 strain NY03. The groups (n = 5 per group) were established based on IgE-bio and/or EHV-1 gC antigen treatments of the foals at
birth: group 1 received IgE-bio and Sav-gC/IL-4 antigen; group 2 received Sav-gC/IL-4 antigen; control group 3 no treatment at birth.
EHV-1 challenge infection occurred at seven months of age (day 0; arrow) and was performed under identical conditions for all three
groups. On day 0, measurements and samples were taken before infection. (A) Body temperatures; the dotted horizontal line shows
the cut-off value for fever (101.5˚F); (B) clinical scores; (C) nasal shedding expressed as viral copy numbers of the EHV-1 gene gB per
ml nasal secretion sample and (D) viremia (gB Ct-value) per 5 x 106 PBMC. Nasal shedding and viremia were evaluated by real-time
PCR. The dotted horizontal line shows the positive PCR Ct-value cut-off value. All negative PCR values were set to this value. All
graphs show means and standard errors per group. Significant differences between groups: a = groups 1 and 3; c = groups 1 and 2.
doi:10.1371/journal.pone.0169072.g001
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enlarged mandibular lymph nodes. Eye discharge and neurological signs were not observed.
Total clinical scores did not differ between groups (Fig 1B).
Quantitative PCR of the EHV-1 gB gene was performed to determine EHV-1 DNA in nasal
secretions and PBMC of the weanlings. EHV-1 DNA was not detected prior to EHV-1 infec-
tion. In the nasal secretion, EHV-1 DNA peaked on day 2 pi, declined to low positive values
between days 3–9 pi, and were still not completely negative by d14 pi (Fig 1C). Viremia was
detectable in all three groups, peaked on day 6 pi, became negative for most weanlings by d11pi
but was still detectable in some horses on d14pi (Fig 1D). Significant differences in the quantity
of EHV-1 DNA in nasal secretion or in PBMC were not observed between the groups.
Antibodies to EHV-1 gC and gD in serum
Anti-gC and anti-gD total Ig in serum did not differ between groups 1 and 2 at any time (Fig
2). In both vaccinated groups, anti-gC total Ig was significantly increased on days 10–14 pi
compared to group 3 (p-values <0.01–0.0001) indicating an earlier onset and higher magni-
tude of EHV-1-specific antibodies in the foals receiving the neonatal EHV-1 gC/IL-4 treat-
ment. The serum anti-gC total Ig of group 1 and 2 foals then reached a plateau. The serum
antibodies in the group 3 weanlings began to rise on day 10 to 19 pi and afterwards reached a
lower mean anti-gC antibody plateau than the two vaccinated groups. Group 3 anti-gC Ig val-
ues were similar to those in groups 1 and 2 on days 19 and 26 pi. However, group 3 anti-gC
antibodies declined again to a significantly lower anti-gC Ig value than the two neonatal vacci-
nation groups on day 40 pi (group 1: p<0.001, group 2: p<0.01) (Fig 2A). Although group 1
and 2 neonates were not vaccinated after birth against EHV-1 gD, anti-gD total Ig responses
also increased earlier in the vaccinated foals than in non-vaccinated controls. This bystander
effect was observed for group 1 on day 10 (p<0.001) and 12 pi (p<0.01), and for group 2 foals
on day 10 pi (p<0.05). Thereafter, anti-gD total Ig values in serum were similar between all
groups (Fig 2B). Total anti-gC antibodies were measured beyond day 40 pi in monthly inter-
vals until day 220 pi. Antibody values slowly decreased over time in all groups and were still
clearly detectable nine months post infection (data not shown). The earlier onset and quantita-
tively higher anti-gC antibody responses shortly after EHV-1 infection suggested that groups 1
and 2 had a pre-existing anti-gC memory B-cell population as a result of the neonatal EHV-1
gC/IL-4 vaccination.
Fig 2. Antibodies to gC and gD in serum of weanlings after experimental EHV-1 infection (day 0; arrow). The weanling groups
correspond to IgE-bio and/or EHV-1 gC antigen treatments during the neonatal period. At weanling age all three groups of weanlings were
infected with the same dose of EHV-1 strain NY03. Antibodies in serum were determined by a EHV-1 Multiplex assay. The graphs show: (A)
total serum anti-EHV-1 gC antibodies and (B) total serum anti-EHV-1 gD antibodies. The graphs represent means and standard errors by
group. Significant differences between groups: a = groups 1 and 3; b = groups 2 and 3.
doi:10.1371/journal.pone.0169072.g002
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Serum isotype responses to EHV-1 gC
If anti-gC memory B-cells existed in the neonatal vaccination groups 1 and 2 at the time of
infection, an earlier onset and higher magnitude IgG isotype and reduced IgM response would
have been expected compared to group 3. This was observed after EHV-1 challenge infection
(Fig 3). Anti-gC IgM antibodies in the vaccinated groups did not increase beyond their base-
line value (Fig 3A). Although the primary IgM response in group 3 was low, an initial anti-gC
IgM increase was observed in the non-vaccinated group 3 on day 4 pi (p<0.05). The initial
anti-gC antibody response in serum after EHV-1 challenge was mainly composed of IgG1 and
IgG1/3 antibodies (Fig 3C and 3D). In the two vaccinated groups, anti-gC IgG1 and IgG3 val-
ues were higher than in group 3 on day 10 pi (IgG1: p<0.01; IgG1/3 p<0.001) supporting that
these two isotypes contributed to the early onset of the antibody response in the vaccinated
weanlings. After day 10 pi, anti-gC IgG1 values were similar in all groups, peaked on days 12–
14 pi and then declined (Fig 3C). Anti-gC IgG1/3 serum antibody values mimicked the IgG1
response for weanlings in groups 1 and 2. However, they were overall higher due to the detec-
tion of both IgG1 and IgG3 isotypes by the antibody used. This suggested that anti-gC IgG3
was also produced in response to EHV-1 infection. Group 3 serum anti-gC IgG1/3 peaked on
day 19 pi and was increased compared to the two vaccinated groups on days 26 (p<0.01) and
40 pi (p<0.001) suggesting an increased production of IgG3 in group 3 that was not noted in
the other two groups (Fig 3D). Similarly, group 3 weanlings responded with low but signifi-
cantly increased anti-gC IgG6 on day 19 pi (p<0.0001), while IgG6 was low in groups 1 and 2
throughout the study (Fig 3B).
Anti-gC IgG4/7 (Fig 3E) overall mimicked the total anti-gC Ig production (Fig 2A). IgG4/7
antibodies were detectable on day 10 pi in the vaccinated groups 1 and 2, increased until day 19
pi, and were then maintained at a plateau level. Group 3 anti-gC IgG4/7 was detectable on day
12 pi, increased slightly by day 14pi, and remained at this level for the rest of the study period.
Compared to group 3, increased IgG4/7 values were observed between days 10–40 pi in group 1
(p-values<0.05–0.0001) and on days 19 and 40 pi in group 2 (p<0.05 and 0.01, respectively
(Fig 3E). Serum anti-gC IgG3/5 antibodies were overall low and almost undetectable in group 3
(Fig 3F). In groups 1 and 2, the amount of anti-gC IgG3/5 was of lower compared to the other
isotypes, showed a similar profile as IgG4/7 antibodies, and were significantly increased com-
pared to group 3 on days 12–40 pi (p-values<0.05–0.0001). Serum IgA antibodies were almost
undetectable in all groups (data not shown).
Overall, the serum anti-gC isotype values supported the earlier onset and overall increased
antibody responses to EHV-1 challenge infection in weanlings that were vaccinated with gC/
IL-4 after birth compared to non-vaccinated group 3 foals. Vaccinated groups were lacking an
IgM response and developed a broad serum anti-gC IgG response with an IgG1/3/4/7/5low
serum isotype profile after challenge infection, while the non-vaccinated weanlings responded
with an initial weak IgM increase followed by a narrow IgG isotype response with an IgG1/3/
4low/6low/7low profile and a delayed onset of all these IgG antibodies.
Cytokine secretion from PBMC after EHV-1 re-stimulation
Cellular immune responses from EHV-1 infected weanlings were measured before and up to
five months post EHV-1 infection. PBMC were re-stimulated with EHV-1 ex-vivo. Secreted IL-
10, IL-4, IFN-γ, and IL-17 were evaluated in PBMC supernatants by multiplex cytokine analysis.
EHV-1 re-stimulation induced substantial IL-10 and low IL-4 secretion from PBMC (Fig 4A
and 4B). In contrast to the control group, PBMC from both neonatal vaccination groups showed
significantly reduced IL-10 secretion on day 7 pi (group 2, p<0.05) or day 8 pi (group 1, p<0.05)
and reduced IL-4 secretion on day 5 pi (both p<0.05). EHV-1 re-stimulation resulted in a sharp
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IFN-γ secretion peak on day 8 pi in all groups (Fig 4C). IL-17 secretion from PBMC was overall
low (Fig 4D). However, IL-17 was increased on day 8 pi in group 2 compared to the other two
groups (both, p<0.0001) and in group 2 compared to group 1 on d17 pi (p<0.05).
Fig 3. Anti-gC isotypes in the serum of weanlings after experimental EHV-1 infection (arrow). Weanlings in group 1 received IgE and
EHV-1 gC antigen at birth. Weanlings in group 2 received EHV-1 gC antigen at birth. Weanlings in the control group 3 did not receive any
treatment at birth. Antibody isotypes to gC were measured in a EHV-1 Multiplex assay. (A) anti-IgM; (B) anti-IgG6; (C) anti-IgG1; (D) anti-
IgG1/3; (E) anti-IgG4/7; (F) anti-gC IgG3/5. The graphs show means and standard errors by group. Significant differences between groups:
a = groups 1 and 3; b = groups 2 and 3.
doi:10.1371/journal.pone.0169072.g003
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In general, EHV-1 re-stimulation of PBMC resulted in a peak of cytokine secretion within
the first 5–8 days pi, which corresponded to peak viremia (day 6 pi). Thereafter, EHV-1 re-
stimulation induced only very low levels of secreted cytokines. At all time points, PBMC ali-
quots were simultaneously stimulated with PMA and ionomycin which provoked high con-
centrations of all four cytokines from these cells at all time points (data not shown). The
finding supports the high immune regulatory capacity of EHV-1 and its ability to effectively
down-regulate EHV-1-specific responses in immune cells.
Cytokines produced by T-cells
EHV-1-specific, CD4+ and CD8+ T-cells were stained for intracellular cytokines and analyzed
by flow cytometry. IL-4, IL-10 or IL-17 were not detectable in T-cells (data not shown). IFN-γ
producing T-cells were observed after EHV-1 infection without significant differences between
groups (Fig 5A). Less than 0.1% EHV-1-specific IFN-γ producing T-cells were detected at all
time points until 9 months pi (Fig 5B). This was in sharp contrast to IFN-γ production from
EHV-1-specific T-cells in adult horses previously exposed to EHV-1 as shown in Fig 5A and
Fig 4. Cytokine secretion from PBMC of weanlings after experimental EHV-1 infection in vivo (arrow). Weanlings in group 1
received IgE and EHV-1 gC antigen as neonates and weanlings in group 2 received EHV-1 gC antigen. Weanlings in the control group 3
did not receive any neonatal. PBMC were isolated up to 5 months post EHV-1 infection. Cells were re-stimulated ex vivo with EHV-1 for
48 hour to provoke cytokine production. PBMC in medium served as non-stimulated control. Cytokines in cell culture supernatants were
determined by cytokine multiplex analysis. The cytokine secretion values in graphs A-D were corrected by the non-stimulated control
values of each weanling and day. The graphs show means and standard errors by group. Significant differences between groups:
a = groups 1 and 3; b = groups 2 and 3; c = groups 1 and 2.
doi:10.1371/journal.pone.0169072.g004
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reported earlier [40]. Nevertheless, total IFN-γ producing EHV-1-specific T-cells appeared in
the peripheral blood in spikes with increasing percentages at days 14, 61 and 150 pi. Total
IFN-γ producing T-cells were elevated compared to the pre-infection percentages on days 61
pi (p<0.001) and 150 pi (p<0.0001). The majority of the EHV-1-specific IFN-γ producing T-
cells were CD8+ cells. Consequently, CD8+/IFN-γ+ cells also peaked on day 61 and 150 pi
(both p<0.0001) and were increased compared to pre-infection values on days 40 and 89 pi
(both p<0.05). Despite their overall very low percentages, CD4+/IFN-γ+ T-cells were increased
on days 61 (p<0.05) and 150 pi (p<0.01) compared to the pre-infection time point.
Overall, the appearance of EHV-1-specific T-cell immunity was late (day 40 pi) compared
to EHV-1 antibody induction that was detectable on day 8–10 pi (Figs 2 & 3). In addition, the
lack of detectable IL-4, IL-10, IL-17 and IFN-γ producing T-cells in the circulating PBMC
until day 8 pi further suggested that the observed secretion of these cytokines from PBMC
Fig 5. EHV-1-specific IFN-g producing T-cells in weanlings (n = 15) after EHV-1 infection (arrow). PBMC were isolated at
different times after infection and were re-stimulated for 48hours with EHV-1 (MOI = 1). Cells were fixed, stained for intracellular IFN-g
and cell surface CD4 and CD8 expression, and were analyzed by flow cytometry. A) Representative images of IFN-g producing CD8
+ T-cells after EHV-1 stimulation. The images from left to right show the cell morphology and the lymphocyte gate; weanling PBMC on
day 61 pi cultured in medium; PBMC from the same weanling re-stimulated with EHV-1; and EHV-1 re-stimulated cells from an adult
horse EHV vaccinated horse. B) Total EHV-1-specic IFN-g producing T-cells and CD4+ or CD8+ IFN-g producing T-cells in the
peripheral blood of the 15 weanlings until day 220 pi. Significant increases compared to the pre-infection control: d = total IFN-g T-cells,
e = CD8+/IFN-g+, f = CD4+/IFN-g+.
doi:10.1371/journal.pone.0169072.g005
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between days 5–8 pi (Fig 4) originated from innate immune cells rather than EHV-1-specific
T-cells.
Discussion
Neonatal B-cell functions and antibody responses to traditional vaccines are reduced com-
pared to adults [14,42,43]. Neonatal vaccination is desirable against many pathogens, includ-
ing EHV-1. It is, however, still a challenge due to the intrinsic functions of the neonatal
immune system such as anti-inflammatory rather than pro-inflammatory responses to innate
immune stimuli, and a trend to immune regulation rather than activation of effector functions
and adaptive immune memory [43]. Coming from the low antigenic environment of the
uterus, the neonatal immune system has to adapt rapidly to multiple environmental and anti-
genic challenges after birth. It is thus not surprising that immune regulation and tolerance to
harmless commensal bacteria or environmental and food antigens dominate the immune
response early in life. In humans and rodent models, neonatal immune responses are charac-
terized by limited plasma cell and germinal center B-cell responses [44]. Neonatal foals also
respond poorly with low antibody amounts to vaccination. Nevertheless, foals start to produce
several IgG isotypes almost immediately after birth [14].
The goal of this neonatal vaccination approach against EHV-1 was to find evidence for the
induction of adaptive B-cell immunity by stimulating innate IL-4 production in basophils and
to use this pathway as a potential new EHV-1 vaccination strategy for neonatal foals. We per-
formed a first vaccination trial using three groups of neonates receiving either (1) IgE-bio and
Sav-gC/IL-4 to stimulate IL-4 production from basophils and activate gC-specific B-cells, or
(2) Sav-gC/IL-4 only to directly activate B-cells without the basophil IL-4 stimulus, or (3) no
neonatal treatment in the control group. We then tested the ability of the neonatal vaccine to
protect these foals from EHV-1 infection and evaluated their humoral and cellular immune
responses.
Clearly, the neonatal EHV-1 gC vaccine used here did not induce any systemically detect-
able gC-specific antibodies after neonatal vaccination which would have been a prerequisite
for a protective EHV-1 vaccine as previously shown in older horses [45,46]. It can be con-
cluded that the induction of antibodies directly after birth would likely require additional com-
ponents or an adjuvant to be added to the vaccine formula. These components would also
need to target innate immune pathways that neonates can perform. Foals almost immediately
start IgG production after birth [14]. In particular, they make considerable amounts of endog-
enous IgG1 and IgG3 antibodies early in life [15,16]. The exact mechanisms by which B-cells
of very young foals are activated to produce IgG in the absence of Th2-immunity are currently
unknown and still need to be unraveled.
In agreement with the missing antibody response after neonatal vaccination was the finding
that none of the weanling groups were fully protected from EHV-1 infection after challenge.
All weanlings developed a fever, mild respiratory clinical signs, nasal EHV-1 shedding and
viremia. All of these parameters observed in weanlings from EHV-1 naïve mares were similar
to those described in previous EHV-1 infection studies in older horses [45–47]. Neurological
signs were not expected after infection with the non-neurogenic NY03 strain and were not
observed. It can be concluded that the missing maternal EHV-1 specific antibody transfer at
birth did not modify clinical signs or severity of the disease in these weanlings compared to
previously performed EHV-1 infection studies in older horses or horses that likely received
maternal EHV-1 specific antibodies.
Despite the lack of antibody production immediately after neonatal vaccination, the experi-
mental infection at weanling age with EHV-1 revealed differences in the foals receiving the
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neonatal EHV-1 gC vaccine compared to the non-vaccinated controls. First, weanlings receiv-
ing IgE-bio and Sav-gC/IL-4 had a significantly lower fever peak after infection indicating the
induction of partial protection from EHV-1 infection in this vaccinated group.
In addition and most remarkably, the two vaccinated weanling groups developed an earlier
and quantitatively higher anti-gC antibody response after EHV-1 challenge compared to non-
vaccinated weanlings. Antibody responses in the vaccinated groups were independent of the
oral IgE-bio treatment at birth. This suggested that a single Sav-gC/IL-4 injection on day 2 of
life is able to induce neonatal B-cell activation. We hypothesize that neonatal B-cell activation
happens for an EHV-1 gC-specific B-cell by crosslinking of gC-specific B-cell receptors and
simultaneous binding of the IL-4 portion of the Sav-gC/IL-4 fusion protein to the IL-4-recep-
tor on the same B-cell. Our results support that this T-cell independent activation mechanism
of equine neonatal gC-specific B-cells likely resulted in a pre-existing memory B-cell popula-
tion that was still present at seven months of age when the EHV-1 infection occurred.
After EHV-1 challenge, the vaccinated groups responded immediately with a serum IgG
response composed of anti-gC IgG1/3/4/7/5low isotypes. The missing IgM response in the vac-
cinated groups further supported the induction of gC-specific IgG memory B-cells by the Sav-
gC/IL-4 antigen at birth. In contrast, non-vaccinated weanlings showed a classical initial anti-
body response to EHV-1, characterized by short-lasting IgM antibodies and followed by a lon-
ger-lasting IgG response against EHV-1 gC. The IgG antibody response of non-vaccinated
weanlings was dominated by IgG1 and IgG3, low IgG4/7 and IgG6, with little to no IgG5 and
was of overall lower isotype variety in comparison to the vaccinated groups. In horses, primary
IgM response are often low (unpublished observations) and some of the classical IgM func-
tions of other species seem to be compensated by equine IgG1 which is the first IgG isotype
observed after infection with many equine pathogens [14] including the EHV-1 infection per-
formed here.
The induction of gC-specific memory B-cells by the neonatal vaccine and in particular by
the single dose injection of Sav-gC/IL-4 antigen still requires confirmation and direct poof of
the existence of these memory B-cells in foals. This is currently a difficult task due to the lack
of memory B-cell specific markers in horses. We have evaluated several memory B-cell mark-
ers directed against mouse and human CD molecules without much success (data not shown).
The identification of memory B-cells in horses thus has to be delayed until a specific marker
for these cells becomes available. However, data from mice indicated that most activated neo-
natal B-cells differentiated in extrafollicular pathways outside of the germinal centers of lym-
phatic tissues. The extrafollicular activation resulted in a quietly residing memory B-cell
population but did not induce IgG producing long-lived plasma cells [43]. A similar mecha-
nism may have occurred here after vaccination with Sav-gC/IL-4 antigen on day 2 of life. This
would offer an explanation for the earlier and increased antibody responses in vaccinated foals
after EHV-1 challenge despite the missing IgG production directly after vaccination.
It was not expected that the neonatal vaccine would affect T-cell responses or other cytokine
responses other than IL-4. After EHV-1 challenge, the evaluation of cellular immune parame-
ters in re-stimulated PBMC confirmed that cytokine and T-cell responses showed no or minor
differences in the vaccinated and non-vaccinated foals. However, the longitudinal analysis of
EHV-1-specific cellular immunity after infection showed several novel results that have not
been reported previously. Most strikingly was the sharp increase of cytokine responses, includ-
ing IL-10 and IFN-γ secretion, from EHV-1 re-stimulated PBMC by the end of the first week
pi. These IL-10 and IFN-γ peaks were followed by a rapid down-regulation of cytokine secre-
tion and a non-responsiveness of PBMC to EHV-1 re-stimulation by and after day 9 pi. In
addition, EHV-1-specific T-cell responses in the EHV-1 infected weanlings were low and
almost undetectable until d40 pi. Afterwards, T-cell responses peaked and declined over time
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and also shifted from the initial CD8+ phenotype on day 61 pi to a CD4+ and CD8+ phenotype
by day 150 pi. These findings confirm the high immune regulatory potential of EHV-1, its abil-
ity to induce systemic suppression of cytokine production and to effectively down-regulate
and modulate T-cell responses.
Conclusions
The novel neonatal vaccination approach described here induced improved antibody responses
and partial protection after foals were challenged by EHV-1 infection. It can be concluded that
the neonatal vaccine, through basophil-derived IL-4 and/or direct gC/IL-4 antigen-mediated
activation of neonatal B-cells, induced a memory B-cell response early in life. Although detect-
able antibody production was missing after vaccination, it is still notable that a single gC/IL-4
antigen injection without adjuvant is sufficient to induce a memory B-cell response in neonatal
foals. These gC-specific memory B-cells were still functional by the time of EHV-1 challenge at
7 months of age. For the development of a fully protective neonatal EHV-1 vaccine additional
vaccine components need to be added to further support the existing neonatal immune func-
tions and to induce EHV-1 antibody production early in life.
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S1 Fig. Conjugation confirmation and functional testing of the neonatal vaccine compo-
nents biotinylated IgE (IgE-bio) and streptavidin-conjugated gC/IL-4 (Sav-gC/IL-4). (A)
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were obtained by MHCII depletion sorting. Afterwards, surface IgE+ cells were stained using
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were harvested, stained for cell surface-bound IgE-bio using Sav-Cy5, and were analyzed by
flow cytometry. (C) Sav-gC/IL-4 was coated to an ELISA plate in different concentrations and
detected with biotin-conjugated peroxidase. After substrate addition, colorimetric development
was measured. (D) MHCIIlow cells from 4 mares were incubated for 20 hours in medium, or
with 1 or 3 ug/ml IgE-bio. Afterwards, all cell culture supernatants were replaced by medium
containing Sav-peroxidase. Cells were incubated for another 24 hours. Then, supernatants were
harvested and IL-4 secretion was quantified in a bead-based assay. Horizontal bars in the graphs
show medians. Significant increases in IgE-bio binding in (B) and IL-4 secretion in (D) com-
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in control group 3 did not receive any treatment after birth. MHCIIlow cells were obtained by
depletion sorting of neonatal foal PBMC on days 2 and 5 of life. Blood samples on day 2 were
obtained before Sav-gC/IL-4 was administrated. MHCIIlow cells were either kept in medium, or
stimulated with Sav-gC/IL-4 or anti-IgE in the presence of the secretion blocker Brefeldin A for
4 hours. Cells were stained afterwards for intracellular IL-4 and cell surface IgE and measured
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